Moving forward in the pre-clinical development of squalene-adenosine nanoparticles : mechanism of action and formulation

Abstract : Adenosine has a high therapeutic potential but its extremely short half-life in blood seriously impairs its efficacy. As presented in the literature review, this difficulty can be overcome by using lipid-based drug delivery systems. Indeed, adenosine can be encapsulated into liposomes or conjugated to a lipid. In particular, among adenosine « lipidizations », the so-called « squalenoylation » has been shown to enhance adenosine biodistribution. This technique consists in coupling adenosine to a lipophilic squalene derivative, thus generating bioconjugates which are able to spontaneously self-assemble as nanoparticles of 100 nm of diameter in aqueous solution. Intravenous injection of these squalene-adenosine (SQAd) nanoparticles led to highly promising results for the treatment of cerebral ischemia and spinal cord injury. Thus, the aim of this thesis was to push forward the pre-clinical development of these nanomedicines following two main directions: unveiling their mechanism of action and enhancing their formulation.Thereby, the first chapter of this thesis presents the results from in vitro study on SQAd nanoparticles mechanism of action. This work has shown that SQAd nanoparticles did not interact directly with adenosine receptors, but formed an intracellular reservoir of adenosine. Indeed, after internalisation, SQAd bioconjugates acted as prodrugs by releasing free adenosine. This molecule was then efflued out of the cells into the extracellular medium, where it could activate specific membrane receptors on neighbouring cells. After studying the mechanism of action, we explored how to optimize the formulation. Results are described in the second chapter. We focus our efforts on freeze-drying the nanoparticles suspension, in order to offer a stable and easy-to-use formulation. Pre-formulation studies were conducted in order to define the optimal conditions for the preservation of nanoparticles physico-chemical properties and for an easy reconstitution of these nanoparticles suspension which can thus be safely injected intravenously. Overall, this work has widen the field of applications for SQAd nanoparticles thanks to a better understanding of their mechanism of action and the development of a formulation which is more suited to clinical needs.
Complete list of metadatas

Cited literature [154 references]  Display  Hide  Download

https://tel.archives-ouvertes.fr/tel-02164724
Contributor : Abes Star <>
Submitted on : Tuesday, June 25, 2019 - 12:19:07 PM
Last modification on : Thursday, June 27, 2019 - 1:25:09 AM

File

75923_ROUQUETTE_2019_archivage...
Version validated by the jury (STAR)

Identifiers

  • HAL Id : tel-02164724, version 1

Collections

Citation

Marie Rouquette. Moving forward in the pre-clinical development of squalene-adenosine nanoparticles : mechanism of action and formulation. Galenic pharmacology. Université Paris-Saclay, 2019. English. ⟨NNT : 2019SACLS035⟩. ⟨tel-02164724⟩

Share

Metrics

Record views

134

Files downloads

69